Corcept CDO William Guyer sells $418,561 in common stock By Investing.com

William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (), sold 3,700 shares of the company’s common stock for a total of $418,561 on August 4, 2026. The sales were executed at prices ranging from $112.92 to $113.455 per share, with a weighted average sale price of $113.1248. The sale comes as CORT shares have surged 210% year-to-date, trading near their 52-week high of $122.21. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value.

Concurrently with the sale, Mr. Guyer acquired 3,700 shares of Corcept common stock by exercising stock options at a price of $21.65 per share, totaling $80,105. InvestingPro subscribers have access to 15 additional ProTips for CORT, plus comprehensive Pro Research Reports covering this and 1,400+ other US equities.

The sale transaction was conducted pursuant to a pre-arranged 10b5-1 trading plan, which Mr. Guyer adopted on November 27, 2024. Following these transactions, Mr. Guyer directly holds 3,985 shares of common stock. This total includes 224 shares, 498 shares, and 877 shares underlying unvested restricted stock awards granted on December 1, 2025, March 2, 2026, and June 1, 2026, respectively. These restricted stock awards are set to vest 100% on the one-year anniversary of their grant date, provided Mr. Guyer satisfies certain requirements. Additionally, Mr. Guyer holds 126,300 stock options.

In other recent news, Corcept Therapeutics announced its second-quarter 2026 financial results, reporting a revenue of $256.1 million. This figure marks a 32% increase from the previous year and surpassed the consensus estimate of $221 million. The company also raised its full-year revenue outlook to a range of $1.1 billion to $1.2 billion, reflecting strong performance in its core Cushing’s syndrome business and the initial sales of LIFYORLI. Following these results, H.C. Wainwright adjusted its price target for Corcept Therapeutics, raising it from $95 to $165 while maintaining a Buy rating. The firm cited the robust quarterly results as a key factor in this decision. These developments highlight Corcept Therapeutics’ ongoing growth and positive market reception.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.